Stockreport

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial  Subjects who have completed [Read more]